Pfizer initiates Phase 2/3 study of potential oral Covid-19 drug
EPIC-PEP study will enrol up to 2,660 healthy participants, aged 18 years and above, who live together with…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
28 Sep 21
EPIC-PEP study will enrol up to 2,660 healthy participants, aged 18 years and above, who live together with…
21 Sep 21
In the trial, Comirnaty showed a neutralising antibody geometric mean titre (GMT) of 1,197.6 in children aged five…
14 Sep 21
The data was based on Phase 3 EBOVAC-Salone clinical study, in which the vaccine regimen was well-tolerated in…
06 Sep 21
Biological E developed Corbevax in partnership with Baylor College of Medicine and biopharmaceutical company Dynavax Technologies
01 Sep 21
The Phase 3 clinical trial will evaluate SK’s vaccine candidate GBP510 against the AstraZeneca/Oxford Covid-19 vaccine
13 Aug 21
The majority of people vaccinated with Moderna’s vaccine maintained both binding and functional antibodies against SARS-CoV-2 variants
10 Aug 21
The Phase 3 trial evaluated the efficacy, safety and pharmacokinetics of Polivy in combination with R-CHP, compared to…
05 Aug 21
The randomised, placebo-controlled, double-blind Phase 2b/3 ALLEGRO trial met the primary efficacy endpoint of improving scalp hair regrowth,…
05 Jul 21
The data included new analysis from blood samples obtained from a subset of participants in the Phase 3…
21 Jun 21
Starpharma claims that its Viraleze is the only nasal spray to show more than 99.9% antiviral activity against…